Select Publications

Blackledge G et al. Response of patients in phase II studies of chemotherapy in ovarian cancer: Implications for patient treatment and design of phase II trials. Br J Cancer 1989;59(4):650-3. Abstract

Coleman RL et al. Early changes in CA125 after treatment with pegylated liposomal doxorubicin or topotecan do not always reflect best response in recurrent ovarian cancer patients. Oncologist 2007;12(1):72-8. Abstract

Gordon AN et al. Recurrent epithelial ovarian carcinoma: A randomized phase III study of pegylated liposomal doxorubicin versus topotecan. J Clin Oncol 2001;19(14):3312-22. Abstract

Markman M et al. Second-line platinum therapy in patients with ovarian cancer previously treated with cisplatin. J Clin Oncol 1991;9(3):389-93. Abstract

Orlando M et al. Randomized trials of combination chemotherapy (combo) versus monotherapy (mono) in relapsed ovarian carcinoma (ROC): A meta-analysis of published data. Proc ASCO 2007;Abstract 5524.

 

 

 

 

 

 

 

 

 

 

 

 

Table of Contents

Top of Page

Home

EDITOR
Neil Love, MD

INTERVIEWS
Deborah K Armstrong, MD
- Select publications

David R Spriggs, MD
- Select publications

Robert L Coleman, MD
- Select publications

Ovarian Cancer Update:
A CME Audio Series and Activity

Faculty Disclosures

Editor's Office